..Italian Laboratory Expands ProtoKinetix’ Market for AAGP™
..Vancouver, British Columbia, December 7th, 2011
...ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) is pleased to announce results from Areta International laboratory in Italy.
..These results show dramatic increases in the production of monoclonal antibodies when AAGP™ is incorporated into the production cycle. Monoclonal antibodies are one of the fastest growing sectors of the pharmaceutical industry. This market is presently over $50-billion USD per year and growing rapidly. As a therapeutic, monoclonal antibodies do not cause the same side-effects of chemotherapy and radiation treatment.
..Since the Company continues to focus on the anti-inflammation applications of AAGP™, they intend to partner the monoclonal antibody development to pharmaceutical laboratories.
..Monoclonal antibodies have proven themselves to be highly effective therapies and diagnostics, in a growing list of diseases. Access to this class of drug is extremely restricted, due to the prohibitive cost.
..In order for monoclonal antibodies to be universally available, the cost has to be aggressively reduced. Initial results from these tests demonstrate a 300% to 500% increase in monoclonal antibody production in the presence of AAGP™.
..This significant increase in yield, will result in major cost reductions for the treatment of cardio vascular disease, auto-immune disorders, leukemia, transplant rejection, cancer as well as numerous diagnostics.